VASP and hyperuricemia: Furthermore, on-treatment residual ADP-inducible platelet reactivity by LTA, the VerifyNow P2Y12 assay, and the VASP assay was significantly higher in patients with hyperuricemia (LTA: Fig. 1a; 53.8% (37–66.7%) vs. 42.9% (31.3–58.2%), p = 0.002; VerifyNow P2Y12 assay: Fig. 1b; 232 PRU (143–303PRU) vs. 190 PRU (126–245 PRU), p = 0.001; VASP assay: 53.4% (33.9–67.5%) vs. 43% (25.1–58.9%), p = 0.002), and there was a trend towards higher platelet aggregation by MEA in response to ADP as compared with patients without hyperuricemia (45 AU (32–60 AU) vs. 38 AU (27–55 AU), p = 0.06).